Terumo Corporation (4543N.MX)
| Previous Close | 280.33 |
| Open | 290.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 274.75 - 274.75 |
| 52 Week Range | 274.75 - 526.05 |
| Volume | |
| Avg. Volume | 13,189 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 16.26 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth
ALISO VIEJO, Calif., September 12, 2024--MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.
- CNW Group
Terumo Establishes Corporate Venture Capital "Terumo Ventures"
Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading the Group's venture investments, as a department within Terumo Americas Holding, Inc.
- Business Wire
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif., July 23, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms. The CLEVER study was a multicenter, prospective study evaluating the WEB 17 system in ruptured and unruptured aneurysms to understand the s
